NCT02711137 2025-10-21
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Incyte Corporation
Phase 1/2 Terminated
Clinical Trials
8 trialsNCT00003727 2019-11-04
Chemotherapy and Peripheral Stem Cell Transplantation Followed by Immunotherapy in Treating Patients With Chronic Myelogenous Leukemia
University of Maryland, Baltimore
Phase 2 Completed
NCT00268242 2018-02-22
Gemcitabine and Mitoxantrone in Treating Patients With Relapsed Acute Myeloid Leukemia
The Cleveland Clinic
Phase 2 Terminated
NCT01428427 2017-11-13
Combination Study of GSK1120212 With Gemcitabine in Subjects With Solid Tumors
GlaxoSmithKline
Phase 1 Completed
NCT00477035 2017-01-11
Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies
Stanford University
Phase 1 Completed
NCT00005829 2016-12-07
Gemcitabine in Treating Patients With Recurrent Chronic Lymphocytic Leukemia
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00410982 2016-06-03
Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid Malignancies
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00006462 2014-02-20
Gemcitabine in Treating Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
Children's Oncology Group
Phase 2 Completed